Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3 STUDY OF 131 I-METAIODOBENZYLGUANIDINE (131I-MIBG) OR CRIZOTINIB ADDED TO INTENSIVE THERAPY FOR CHILDREN WITH NEWLY DISAGNOSED HIGH-RISK NEUROBLASTOMA (NBL) (IND# 134379)

Intervention/treatment:
CRIZOTINIB / MIBG I-131 (IOBENGUANE) / CARBOPLATIN / CISPLATIN / CYCLOPHOSPHAMIDE / UNITUXIN / ETOPOSIDE / ETOPOSIDE PHOSPHATE/ MELPHALAN / SARGRAMOSTIM / THIOTEPA / TOPOTECAN
Medical condition:
NEUROBLASTOMA
Protocol code:
ANBL1531
Control number:
219331
Status:
Recruiting
Approved:
September 17, 2018
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03126916
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
365 Days to 30 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Sponsor
CHILDRENS ONCOLOGY GROUP

Locations

British Columbia

British Columbia Children's Hospital
Vancouver, British Columbia, V6H 3V4
SUSPENDED

Manitoba

CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
SUSPENDED
Name
Site Public Contact
Role
CONTACT
Phone:
866-561-1026
Name
Stephanie M. Villeneuve
Role
PRINCIPAL_INVESTIGATOR

Newfoundland and Labrador

Janeway Child Health Centre
St. John's, Newfoundland and Labrador, A1B 3V6
SUSPENDED
Name
Site Public Contact
Role
CONTACT
Phone:
709-777-8727
Name
Lisa A. Goodyear
Role
PRINCIPAL_INVESTIGATOR

Nova Scotia

IWK Health Centre
Halifax, Nova Scotia, B3K 6R8
SUSPENDED
Name
Site Public Contact
Role
CONTACT
Phone:
902-470-8520
Name
Craig Erker
Role
PRINCIPAL_INVESTIGATOR

Ontario

Children's Hospital
London, Ontario, N6A 5W9
SUSPENDED
Name
Site Public Contact
Role
CONTACT
Phone:
519-685-8306
Name
Shayna M. Zelcer
Role
PRINCIPAL_INVESTIGATOR
Children's Hospital of Eastern Ontario
Ottawa, Ontario, K1H 8L1
SUSPENDED
Name
Site Public Contact
Role
CONTACT
Phone:
613-737-7600
Name
Donna L. Johnston
Role
PRINCIPAL_INVESTIGATOR
Hospital for Sick Children
Toronto, Ontario, M5G 1X8
SUSPENDED
Name
Site Public Contact
Role
CONTACT
Phone:
416-813-7654
Name
Daniel A. Morgenstern
Role
PRINCIPAL_INVESTIGATOR
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7
SUSPENDED
Name
Site Public Contact
Role
CONTACT
Phone:
613-549-6666
Name
Laura Wheaton
Role
PRINCIPAL_INVESTIGATOR
McMaster Children's Hospital at Hamilton Health Sciences
Hamilton, Ontario, L8N 3Z5
SUSPENDED
Did you find what you were looking for?

Contacts and resources